Presentació
La Unitat de Tuberculosi Experimental (UTE) és un grup de recerca de l'IGTP associat al Servei de Microbiologia de l'Hospital Universitari Germans Trias i Pujol (HUGTIP) i al Departament de Genètica i Microbiologia de la Universitat Autònoma de Barcelona. El grup està dirigit per la Dra. Cristina Vilaplana i està acreditat per l'AGAUR (2021 SGR 00920). La missió del grup és millorar la qualitat de vida dels pacients amb tuberculosi mitjançant un diagnòstic més ràpid i fiable, un millor abordatge clínic, millors tractaments i millors desenllaços de la malaltia. La seva visió és tenir una gran repercussió en la lluita contra la tuberculosi, sent al mateix temps competitiu a nivell internacional.
Paraules clau: tuberculosi, microbiologia, malalties infeccioses, estudis clínics, assajos clínics, pronòstic, tractaments, models experimentals, immunologia, cirurgia pulmonar, desenvolupament de fàrmacs, desenvolupament de vacunes, qualitat de vida relacionada amb la salut.
_1687174037.jpg)
Equip
Pere-Joan Cardona Iglesias (ELIMINAR)
Jordi Bechini Bernard (ELIMINAR)
Laura Villegas Bullon (ELIMINAR)
Lilibeth Arias De la Cruz (ELIMINAR)
Ricardo Perez Andres (ELIMINAR)
Montserrat Tenesa Bordas (ELIMINAR)
Silvia Roure Díez (ELIMINAR)
Kaory Levy Da Fonseca (ELIMINAR)
Marta Arch Sisquella (ELIMINAR)
Línies de recerca
Study of biomarkers and tools for monitoring TB disease course and prognosis
The lack of a validated correlator of protection as well as biomarkers to monitor the disease course or prognosis is still one of the main impairements on improving the clinical management of TB. The group aims to identify and validate biomarkers able to monitor treatment response and to predict TB disease course and outcomes (prognosis). The team also aims to develop and evaluate tools and strategies to improve the clinical management of patients and their quality of life. The final aim of this strategic objective is to be able to stratify patients during clinical management. The group is leading several cohort studies which have allowed them to build a large unique collection of samples (lung tissue, blood and urine) to perform these studies.
Evaluation of new prophylactic and therapeutic strategies against TB
The UTE has more than 15 years of expertise in the evaluation of new prophylactic and therapeutic strategies against TB, both in experimental models (in vivo, in vitro and in silico) and in clinical trials and studies. Because of this experience, the UTE has become an international reference to evaluate new drug and vaccine candidates and has been included in several international consortia (funded by the EC and the Bill & Melinda Gates Foundation). The group has also been contracted by several research sites and biotech & pharma companies. Depending on the final aim of the contractor, the unit has a wide portfolio of experimental animal models and services, as well as expertise to lead and coordinate randomised clinical trials in the context of tuberculosis research. For this research line, their link to the Microbiology Dept. of the Germans Trias i Pujol University Hospital and the access to the unique Centre for Comparative Medicine and Bioimage of Catalonia (CMCiB) facility are key.
Study of health dimensions and quality of life in the context of infectious diseases
As TB is a disease linked to socio-economic factors and vulnerable populations, and with the belief that there are several dimensions of health (physical, social, emotional, environmental, etc.) and changes in one affect the others, the group aims not only to study TB as a disease, but also to understand the individual with TB. Within this research line, the team studies the impact of TB on the health dimensions and quality of life of TB patients in the context of all their clinical studies and trials. They also conduct community outreach activities to increase TB awareness and decrease TB diagnostic delay in which patients and public are involved, especially in socio-economic deprived areas and among vulnerable populations.
Projectes actius
SMA-TB: A novel Stratified Medicine Algorithm to predict treatment responses to host-directed therapy in TB Patients. (H2020-SC1-BHC-2018-2020)
PI: Cristina Vilaplana
Funding agency: European Commission
Agency code: GA 847762
Duration: 2020 - 2024
More information
Repository
Towards a better understanding and control of tuberculosis
PI: Pere-Joan Cardona
Funding agency: Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES)
Agency code: CIBERESTB2325
Duration: 2023 - 2025
New Research and Innovation on Tuberculosis: Prevention, Diagnosis and Treatment
PI: Pere-Joan Cardona
Funding agency: Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES)
Agency code: CB06/06/0031
Start date: 2016
Unitat de Tuberculosi Experimental
PI: Cristina Vilaplana
Funding agency: Agencia de Gestió d'Ajuts Universitaris de Recerca (AGAUR)
Agency code: 2021 SGR 00920
Duration: 2022 - 2024
ITHEMYC: Novel immunotherapies for tuberculosis and other mycobacterial diseases
PI: Pere-Joan Cardona
Funding agency: European Commission
Agency code: proposal nº 101080462-2
Duration: 2023 - 2026
Ajuts Margarita Salas Modalitat de 2 anys
PI: Cristina Vilaplana
Funding agency: Universitat Autònoma de Barcelona
Agency code: 720452
Duration: 2022 - 2024
Past projects
Búsqueda de biomarcadores pronósticos para personalizar el tratamiento de la tuberculosis
PI: Cristina Vilaplana
Funding agency: Instituto de Salud Carlos III
Agency code: PI20/01424
Duration: 2021 - 2023
Estudio de las bases biológicas de la susceptibilidad a la tuberculosis según el sexo. Importancia del eje hipotalámico-pituitarioadrenal
PI: Pere-Joan Cardona
Funding agency: Instituto de Salud Carlos III
Agency code: PI20/01431
Duration: 2021 - 2023
EpiPose: Epidemic intelligence to minimize COVID-19's public health, societal and economical impact
PI: Cristina Vilaplana
Funding agency: H2020 - European Commission
Agency code: 101003688
Duration: 2020 - 2023
In Silico Trial for Tuberculosis Vaccine Development (STRITUVAD)
Co-PI: Pere-Joan Cardona
Funding agency: H2020-SC1-2017-CNECT-2 - European Commission
Agency code: 777123
Duration: 2018 - 2022
Programme for the progressive substitution of laboratory animals in the Center for Comparative Medicine (IGTP) (CMCiB-3R)
PI: Pere-Joan Cardona
Funding agency: La Caixa
Agency code: LCF/PR/GN17/50300003
Duration: 2018 - 2022
Publicacions científiques
Highlighted publications
Prats C, Vilaplana C, Valls J, Marzo E, Cardona PJ, López D. Local Inflammation, Dissemination and Coalescence of Lesions Are Key for the Progression toward Active Tuberculosis: The Bubble Model. Front Microbiol. 2016 Feb 2;7:33. DOI: 10.3389/fmicb.2016.00033. PMID: 26870005; PMCID: PMC4736263.
Arias L, Cardona P, Català M, Campo-Pérez V, Prats C, Vilaplana C, Julián E, Cardona PJ. Cording Mycobacterium tuberculosis Bacilli Have a Key Role in the Progression towards Active Tuberculosis, Which is Stopped by Previous Immune Response. Microorganisms. 2020 Feb 8;8(2):228. DOI: 10.3390/microorganisms8020228. PMID: 32046344; PMCID: PMC7074780.
Melkie ST, Arias L, Farroni C, Jankovic Makek M, Goletti D, Vilaplana C. The role of antibodies in tuberculosis diagnosis, prophylaxis and therapy: a review from the ESGMYC study group. Eur Respir Rev. 2022 Mar 9;31(163):210218. DOI: 10.1183/16000617.0218-2021. PMID: 35264411; PMCID: PMC9489037.
Informació addicional
Collaborative networks
- CIBERES (ISCIII). Group CB06/06/0031
- COST Action CA21164 (financed by European Commission’s Horizon Europe). More information
- TBnet. More information
- VALIDATE. More information
- CTVD (Bill & Melinda Gates Foundation). More information
- Study Group on Mycobacterial Infections (ESGMYC) of the European Society of Clinical Microbiology and Infectious Diseases
Doctoral theses
Title: Avaluació d'eines per a un maneig assistencial més personalitzat, integral i eficaç per a les persones amb tuberculosi (Evaluation of tools for a more personalized, comprehensive, and effective care management for individuals with tuberculosis)
Author: Arantxa Romero Tamarit
University: Universitat Autònoma de Barcelona (UAB), Genetics and Microbiology Dept.
Date of defense: 11/12/2023
Notícies
Destacada representació de l’IGTP a la Nit de la Recerca
Diversos investigadors de l'IGTP han participat en la Nit de la Recerca d'enguany a Barcelona. Han compartit el seu impuls per la ciència amb xerrades i transportat els assistents d'un taller, a través d'un joc de taula, a una epidèmia de tuberculosi.
L’IGTP apropa la ciència a estudiants de primària de Badalona
Investigadors i investigadores de l'IGTP han participat a la 2ª Fira de Ciència al carrer d'ESO amb mirada STEAM. Juntament amb estudiants de vuit centres d'educació secundària i altres centres de recerca i empreses, han mostrat conceptes científics a alumnes de cinquè de primària de Badalona a través de diversos tallers.
Contacte
(+34) 93 033 0527
Laura Villegas
Més enllaços
UTE Blog · Follow @tbexperimental on X · Donate via Amics de Can Ruti, projecte Nyaditum · Donate via Amics de Can Ruti, marcadors pronòstics · Donate via Amics de Can Ruti, projecte RESIL